Trial Profile
Phase II trial evaluating efficacy and tolerability of ISIS EIF4ERx in combination with docetaxel and prednisone in patients with castration-resistant prostate cancer
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2011
Price :
$35
*
At a glance
- Drugs ISIS EIF4ERx (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 05 Jan 2011 New trial record